What is Retacrit used for (its approved indications)?
Retacrit (epoetin alfa-epbx) is an erythropoiesis-stimulating agent used to treat certain types of anemia, including:
- Anemia in patients with chronic kidney disease (CKD), including patients on dialysis.
- Anemia in patients with cancer receiving chemotherapy, where the chemotherapy causes the patient’s anemia and the intent is not curative.
Who is it indicated for versus who is it not for?
Retacrit’s use is tied to specific settings of anemia:
- It is indicated for anemia related to CKD and for anemia related to chemotherapy treatment in eligible cancer patients.
- It is not an all-purpose treatment for any anemia; it is not indicated for anemia caused by other conditions (for example, iron deficiency alone) unless those conditions are also being managed appropriately.
What conditions can overlap with Retacrit use?
In practice, patients considered for Retacrit typically also have other anemia drivers that must be evaluated and corrected as needed, such as iron deficiency. Retacrit is used when the anemia situation matches the approved indication and when clinicians manage contributing factors.
What might patients search next: dosing start criteria
People often follow up on:
- how low hemoglobin must be before starting,
- when to monitor hemoglobin,
- and what dose adjustments are used if hemoglobin rises too quickly.
If you tell me the patient category you mean (CKD on dialysis, CKD not on dialysis, or cancer on chemotherapy), I can tailor the indication description to that exact group.